Register Today

www.ResearchToPractice.com/Meetings/IASLC2019/SCLC

If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

This event is free of charge.

Fairmont Chicago, Millennium Park
200 North Columbus Drive
Chicago, IL 60601

Hotel Phone: (312) 565-8000

Meeting Room: Rouge Room (Lobby Level)

The Fairmont Chicago, Millennium Park is the host hotel for the IASLC 2019 North America Conference on Lung Cancer.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

Research
To Practice®

One Biscayne Tower
2 South Biscayne Boulevard
Suite 3600
Miami, FL 33131

Meet The Professors

Clinical Investigators Provide Perspectives on the Integration of Immune Checkpoint Inhibitors into the Management of Small Cell Lung Cancer

A CME Program During the IASLC 2019 North America Conference on Lung Cancer

When
Friday, October 11, 2019

11:15 AM – 11:30 AM
Registration and Lunch Buffet

11:30 AM – 12:30 PM
Educational Program

Where
Fairmont Chicago
Millennium Park
200 North Columbus Drive
Chicago, Illinois

Rouge Room (Lobby Level)

Faculty
Anna F Farago, MD, PhD
Ramaswamy Govindan, MD

Moderator
David R Spigel, MD

Register Today
www.ResearchToPractice.com/Meetings/IASLC2019/SCLC
There is no registration fee for attending this meeting.

CME Certified

Research To Practice®

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

This program was approved by the IASLC 2019 North America Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 North America Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

CME Information

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of small cell lung cancer (SCLC).

Learning Objectives
At the conclusion of this activity, participants should be able to:

- Formulate up-to-date management strategies for patients with SCLC, considering the roles of local therapy, chemotherapy and immunotherapy.
- Appraise available and emerging research data and current guideline recommendations informing the use of immune checkpoint inhibitors for patients with SCLC, and discern how these agents can be optimally employed in clinical practice.
- Review the recent FDA approval of atezolizumab in combination with carboplatin and etoposide as first-line therapy for patients with extensive-stage SCLC, and consider how this strategy can be appropriately and safely integrated into clinical practice.
- Appreciate emerging Phase III data investigating the role of durvalumab in combination with platinum-based chemotherapy for newly diagnosed extensive-stage SCLC, and apply this information to identify patients who may be appropriate for future treatment with this novel approach.
- Recall the design of ongoing clinical trials evaluating other anti-PD-1/PD-L1-based strategies in SCLC, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Faculty

Anna F Farago, MD, PhD
Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Ramaswamy Govindan, MD
Professor of Medicine
Director, Section of Oncology
Anheuser-Busch Endowed Chair in Medical Oncology
Washington University School of Medicine
St Louis, Missouri

Moderator

David R Spigel, MD
Chief Scientific Officer
Program Director
Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

Practicing clinicians in attendance will be provided with a networked iPad® to use at the event to complete a premeeting survey and submit questions directly to the moderator for additional discussion.

Meeting Format and Agenda

This unique activity will feature 3 separate content modules during which a noted investigator will review available data sets, present cases from his or her practice and provide perspectives on key clinical questions as part of a moderated discussion. The event will not include traditional didactic lectures.

EACH MODULE WILL FOLLOW AN IDENTICAL FORMAT:





MODULE 1: Current and Future Management of Patients with Newly Diagnosed Extensive-Stage (ES) Small Cell Lung Carcinoma (SCLC)

- Key efficacy findings from the Phase III IMpower133 trial evaluating carboplatin plus etoposide with or without atezolizumab for untreated ES-SCLC
- FDA approval of first-line carboplatin/etoposide/atezolizumab and appropriate integration into current SCLC management
- Design, eligibility criteria and primary and secondary endpoints from the Phase III CASPIAN trial evaluating durvalumab or durvalumab plus tremelimumab in combination with platinum-based chemotherapy versus chemotherapy alone as first-line treatment for patients with ES-SCLC
- Similarities and differences between designs of CASPIAN and IMpower133
- Emerging results from CASPIAN documenting the benefit of durvalumab in combination with etoposide and platinum-based chemotherapy versus chemotherapy alone as first-line therapy for ES-SCLC
- Potential role of durvalumab/etoposide/platinum chemotherapy in the management of previously untreated ES-SCLC

MODULE 2: Management of Progressive ES-SCLC

- Key factors influencing the selection of therapy for patients with progressive ES-SCLC (eg, number of prior lines of therapy, duration of response to last line of therapy)
- Optimal sequencing of available therapies including immune checkpoint inhibitors for patients with R/R ES-SCLC
- Research database supporting the FDA approvals of nivolumab and pembrolizumab for patients with SCLC that has progressed after two or more lines of therapy
- Available clinical trial data with anti-PD-1/PD-L1 antibodies in combination with anti-CTLA-4 antibodies; current role of nivolumab/ipilimumab in clinical practice
- Ongoing clinical trials evaluating anti-PD-1/PD-L1-based approaches for patients with LS- and ES-SCLC

MODULE 3: Recognizing and Managing Immune-Related Adverse Events (IrAEs) with Checkpoint Inhibitor Therapy in SCLC

- Pathophysiology of common and uncommon adverse events observed with the use of anti-PD-1/PD-L1 antibodies alone or in combination with other systemic approaches
- Incidence, severity, and timing of IrAEs (eg, pneumonitis, dermatologic AEs, GI-related AEs, endocrinologic AEs) in Phase III IMpower133 and CASPIAN trials
- Published safety findings with anti-PD-1/PD-L1 monotherapy in ES-SCLC
- Recommended algorithms for the management of IrAEs; dose, duration, and timing of corticosteroid use; recommendations for restarting immune checkpoint inhibitor therapy following resolution of symptoms
- Role, if any, of immune checkpoint inhibitor therapy in SCLC for patients with pre-existing autoimmune disease and other conditions (eg, organ transplant, paraneoplastic syndrome, SIADH)